Just out - approval by the TSX Venture Exchange
Ventripoint Diagnostics prospectus offering
2021-11-01 17:22 ET - Prospectus Approved
Effective Oct. 14, 2021, the company's final short form prospectus dated Oct. 13, 2021, qualifying the distribution of up to 13.47 million of the company, excluding underwriters' overallotment option, was filed with and accepted by the TSX Venture Exchange, and filed with and receipted by the Ontario Securities Commission, as principal regulator. Under Multilateral Instrument 11-102, Passport System, the prospectus is deemed to have been filed with and receipted by each of the British Columbia, Alberta and Saskatchewan securities commissions.
The exchange has been advised that closing occurred on Oct. 20, 2021, for aggregate gross proceeds of $8,055,060 (including the underwriters' overallotment option, which was exercised in full).
Offering: 15,490,500 units (includes 2,020,500 units of the underwriter's overallotment option) (Each unit consists of one common share and one common share purchase warrant, with each warrant being exercisable into one common share at 70 cents for a 60-month period, subject to accelerated expiry in certain circumstances.)
Unit price: 52 cents per unit
Underwriters: Leede Jones Gable Inc. and Stifel Nicolaus Canada Inc.
Underwriters commissions: an aggregate of $535,774 in cash and 1,030,335 non-transferable broker warrants (Each broker warrant entitles the holder to acquire one unit at 52 cents for a 60-month period.)
For further details, please refer to the company's short form prospectus dated Oct. 13, 2021, and news releases dated Sept. 27, 2021, Sept. 28, 2021, Oct. 1, 2021, and Oct. 20, 2021.